 Home > Biochemistry News > Biotechnology News > Using B cells to cross the blood-brain barrier to deliver protein drugs to help develop new cell therapies

Using B cells to cross the blood-brain barrier to deliver protein drugs to help develop new cell therapies

 Last Update: 2021-10-19
 Source: Internet
 Author: User

Tags

power cell battery

hiv treatment drugs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 13, 2021, Immusoft announced that it has signed a research cooperation and licensing option agreement with Takeda, which will use Immusoft’s immune system programming ISP technology platform to discover, develop and commercialize transformative cell therapies for Treatment of rare genetic metabolic disorders

The ISP (Immune system Programming) platform can use the patient's own cells to achieve continuous delivery of protein therapy

According to the terms of the agreement, Immusoft will receive an undisclosed advance payment and research funding support, and is eligible for milestone payments, the total amount can exceed 900 million US dollars

Reference materials:

[1] Immusoft And Takeda Collaborate To Discover And Develop Cell Therapies For Rare Neurometabolic Disorders.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express uses B cells to cross the blood-brain barrier to deliver protein drugs, and US$900 million helps develop new cell therapies

10-21

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Using B cells to cross the blood-brain barrier to deliver protein drugs to help develop new cell therapies

Related Articles

Express uses B cells to cross the blood-brain barrier to deliver protein drugs, and US$900 million helps develop new cell therapies